Article By:
Zacks Investment Research
Saturday, June 11, 2022 3:00 PM EDT
New drug approvals, acquisitions, and other pipeline developments are back in the spotlight in the biotech industry, following the focus on the development of vaccines and antibody treatments for COVID-19 in the last two years.